Cargando…

Testing the performance of risk prediction models to determine progression to referable diabetic retinopathy in an Irish type 2 diabetes cohort

BACKGROUND /AIMS: To evaluate the performance of existing prediction models to determine risk of progression to referable diabetic retinopathy (RDR) using data from a prospective Irish cohort of people with type 2 diabetes (T2D). METHODS: A cohort of 939 people with T2D followed prospectively was us...

Descripción completa

Detalles Bibliográficos
Autores principales: Smith, John J, Wright, David M, Stratton, Irene M, Scanlon, Peter Henry, Lois, Noemi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9340042/
https://www.ncbi.nlm.nih.gov/pubmed/33903145
http://dx.doi.org/10.1136/bjophthalmol-2020-318570
_version_ 1784760309801549824
author Smith, John J
Wright, David M
Stratton, Irene M
Scanlon, Peter Henry
Lois, Noemi
author_facet Smith, John J
Wright, David M
Stratton, Irene M
Scanlon, Peter Henry
Lois, Noemi
author_sort Smith, John J
collection PubMed
description BACKGROUND /AIMS: To evaluate the performance of existing prediction models to determine risk of progression to referable diabetic retinopathy (RDR) using data from a prospective Irish cohort of people with type 2 diabetes (T2D). METHODS: A cohort of 939 people with T2D followed prospectively was used to test the performance of risk prediction models developed in Gloucester, UK, and Iceland. Observed risk of progression to RDR in the Irish cohort was compared with that derived from each of the prediction models evaluated. Receiver operating characteristic curves assessed models’ performance. RESULTS: The cohort was followed for a total of 2929 person years during which 2906 screening episodes occurred. Among 939 individuals followed, there were 40 referrals (4%) for diabetic maculopathy, pre-proliferative DR and proliferative DR. The original Gloucester model, which includes results of two consecutive retinal screenings; a model incorporating, in addition, systemic biomarkers (HbA1c and serum cholesterol); and a model including results of one retinopathy screening, HbA1c, total cholesterol and duration of diabetes, had acceptable discriminatory power (area under the curve (AUC) of 0.69, 0.76 and 0.77, respectively). The Icelandic model, which combined retinopathy grading, duration and type of diabetes, HbA1c and systolic blood pressure, performed very similarly (AUC of 0.74). CONCLUSION: In an Irish cohort of people with T2D, the prediction models tested had an acceptable performance identifying those at risk of progression to RDR. These risk models would be useful in establishing more personalised screening intervals for people with T2D.
format Online
Article
Text
id pubmed-9340042
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-93400422022-08-16 Testing the performance of risk prediction models to determine progression to referable diabetic retinopathy in an Irish type 2 diabetes cohort Smith, John J Wright, David M Stratton, Irene M Scanlon, Peter Henry Lois, Noemi Br J Ophthalmol Clinical Science BACKGROUND /AIMS: To evaluate the performance of existing prediction models to determine risk of progression to referable diabetic retinopathy (RDR) using data from a prospective Irish cohort of people with type 2 diabetes (T2D). METHODS: A cohort of 939 people with T2D followed prospectively was used to test the performance of risk prediction models developed in Gloucester, UK, and Iceland. Observed risk of progression to RDR in the Irish cohort was compared with that derived from each of the prediction models evaluated. Receiver operating characteristic curves assessed models’ performance. RESULTS: The cohort was followed for a total of 2929 person years during which 2906 screening episodes occurred. Among 939 individuals followed, there were 40 referrals (4%) for diabetic maculopathy, pre-proliferative DR and proliferative DR. The original Gloucester model, which includes results of two consecutive retinal screenings; a model incorporating, in addition, systemic biomarkers (HbA1c and serum cholesterol); and a model including results of one retinopathy screening, HbA1c, total cholesterol and duration of diabetes, had acceptable discriminatory power (area under the curve (AUC) of 0.69, 0.76 and 0.77, respectively). The Icelandic model, which combined retinopathy grading, duration and type of diabetes, HbA1c and systolic blood pressure, performed very similarly (AUC of 0.74). CONCLUSION: In an Irish cohort of people with T2D, the prediction models tested had an acceptable performance identifying those at risk of progression to RDR. These risk models would be useful in establishing more personalised screening intervals for people with T2D. BMJ Publishing Group 2022-08 2021-04-26 /pmc/articles/PMC9340042/ /pubmed/33903145 http://dx.doi.org/10.1136/bjophthalmol-2020-318570 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.
spellingShingle Clinical Science
Smith, John J
Wright, David M
Stratton, Irene M
Scanlon, Peter Henry
Lois, Noemi
Testing the performance of risk prediction models to determine progression to referable diabetic retinopathy in an Irish type 2 diabetes cohort
title Testing the performance of risk prediction models to determine progression to referable diabetic retinopathy in an Irish type 2 diabetes cohort
title_full Testing the performance of risk prediction models to determine progression to referable diabetic retinopathy in an Irish type 2 diabetes cohort
title_fullStr Testing the performance of risk prediction models to determine progression to referable diabetic retinopathy in an Irish type 2 diabetes cohort
title_full_unstemmed Testing the performance of risk prediction models to determine progression to referable diabetic retinopathy in an Irish type 2 diabetes cohort
title_short Testing the performance of risk prediction models to determine progression to referable diabetic retinopathy in an Irish type 2 diabetes cohort
title_sort testing the performance of risk prediction models to determine progression to referable diabetic retinopathy in an irish type 2 diabetes cohort
topic Clinical Science
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9340042/
https://www.ncbi.nlm.nih.gov/pubmed/33903145
http://dx.doi.org/10.1136/bjophthalmol-2020-318570
work_keys_str_mv AT smithjohnj testingtheperformanceofriskpredictionmodelstodetermineprogressiontoreferablediabeticretinopathyinanirishtype2diabetescohort
AT wrightdavidm testingtheperformanceofriskpredictionmodelstodetermineprogressiontoreferablediabeticretinopathyinanirishtype2diabetescohort
AT strattonirenem testingtheperformanceofriskpredictionmodelstodetermineprogressiontoreferablediabeticretinopathyinanirishtype2diabetescohort
AT scanlonpeterhenry testingtheperformanceofriskpredictionmodelstodetermineprogressiontoreferablediabeticretinopathyinanirishtype2diabetescohort
AT loisnoemi testingtheperformanceofriskpredictionmodelstodetermineprogressiontoreferablediabeticretinopathyinanirishtype2diabetescohort